Cargando…

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales:	Eyre, Toby A., Lamanna, Nicole, Roeker, Lindsey E., Ujjani, Chaitra S, Hill, Brian T., Barr, Paul M., Lansigan, Erick, Cheson, Bruce D., Yazdy, Maryam, Allan, John N., Rhodes, Joanna, Schuster, Stephen J., Nabhan, Chadi, Skarbnik, Alan, Leslie, Lorie, Islam, Prioty, Whitaker, Katherine, Coombs, Catherine C., Tuncer, Hande H., Pagel, John M., Jacobs, Ryan, Winter, Allison M., Bailey, Neil, Sitlinger, Andrea, Schuh, Anna H., Follows, George, Fox, Christopher P., Brander, Danielle M., Shadman, Mazyar, Mato, Anthony R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776352/ https://www.ncbi.nlm.nih.gov/pubmed/32079693 http://dx.doi.org/10.3324/haematol.2019.241539

Ejemplares similares

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL
por: Rhodes, Joanna, et al.
Publicado: (2023)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY
por: Lansigan, Frederick, et al.
Publicado: (2023)

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
por: Mato, Anthony R., et al.
Publicado: (2018)

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
por: Hill, Joshua A., et al.
Publicado: (2021)

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
por: Mato, Anthony R., et al.
Publicado: (2018)

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
por: Cuneo, Antonio, et al.
Publicado: (2020)

Impact of obinutuzumab alone and in combination for follicular lymphoma
por: Sarraf Yazdy, Maryam, et al.
Publicado: (2017)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat
por: Raychaudhuri, Ruben, et al.
Publicado: (2022)

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
por: Roeker, Lindsey E., et al.
Publicado: (2021)

The potential of pirtobrutinib in multiple B-cell malignancies
por: Jensen, Jeffrey L., et al.
Publicado: (2022)

Primary effusion lymphoma: current perspectives
por: Narkhede, Mayur, et al.
Publicado: (2018)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
por: Mato, Anthony R., et al.
Publicado: (2020)

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2020)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2022)

Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions
por: Mato, Anthony R., et al.
Publicado: (2022)

Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration
por: Stephens, Deborah M., et al.
Publicado: (2020)

Hematopoietic Cell Transplantation for Older Patients with MDS
por: Shadman, Mazyar, et al.
Publicado: (2014)

Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures
por: Graf, Solomon A., et al.
Publicado: (2021)

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study
por: Iovino, Lorenzo, et al.
Publicado: (2022)

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
por: Graf, Solomon A., et al.
Publicado: (2022)

Childhood trauma fatality and resource allocation in injury control programs in a developing country
por: Roudsari, Bahman S, et al.
Publicado: (2006)

All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia
por: Thompson, Meghan C., et al.
Publicado: (2021)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Two Doctors, One Patient, and a Common Goal
por: Nabhan, Chadi, et al.
Publicado: (2018)

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022)

High-Intensity Interval Training in Older Adults With Treatment Naive Chronic Lymphocytic Leukemia
por: Bartlett, David, et al.
Publicado: (2021)

P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT
por: Shadman, Mazyar, et al.
Publicado: (2023)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States
por: Nabhan, Chadi, et al.
Publicado: (2017)

The Impact of B-Cell-Directed Therapy on Sars-Cov-2 Vaccine Efficacy in CLL: 1-Year Follow up
por: Ujjani, Chaitra S., et al.
Publicado: (2022)

Concurrent Diagnosis of Chronic Myeloid Leukemia and Follicular Lymphoma: An Unreported Presentation
por: Starr, Amy G., et al.
Publicado: (2018)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

P1097: CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY
por: Shadman, Mazyar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7ksbmekie6b2j0rfvsokn70fpo